Veradermics reports positive Phase 2/3 results for oral Rogaine in men with pattern hair loss

Veradermics, a biotech that recently went public, announced that its oral formulation of Rogaine met the primary endpoints in a late-stage Phase 2/3 trial.

The study enrolled men with mild-to-moderate pattern hair loss and showed statistically significant improvement in hair growth compared with placebo, confirming the drug’s efficacy.

This successful readout represents the company’s first major milestone as a public entity and could position the oral product for further development and potential market entry.